Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19364130 | 0.89 | P2RX3 (0.85) | P2RX3P2RX2 | |
| SCHEMBL29839524 | 0.89 | P2RX3 (0.72) | P2RX3P2RX2 | |
| SCHEMBL22439646 | 0.89 | P2RX3 (0.72) | P2RX3P2RX2 | |
| SCHEMBL24692985 | 0.89 | P2RX3 (0.61) | P2RX3P2RX2 | |
| SCHEMBL22439302 | 0.88 | P2RX3 (0.71) | P2RX3P2RX2 | |
| SCHEMBL29839480 | 0.88 | P2RX3 (0.71) | P2RX3P2RX2 | |
| SCHEMBL5004953 | 0.85 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL22448731 | 0.84 | P2RX3 (0.73) | P2RX3P2RX2 | |
| SCHEMBL22439573 | 0.84 | P2RX3 (0.66) | P2RX3P2RX2 | |
| SCHEMBL30119597 | 0.84 | P2RX3 (0.66) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20220211703-A1 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| US-20210179648-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3712144-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179648-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885 |
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885 |
| US-20220211703-A1 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | NUDT1, DPYD, PEPD | P2RX3 276/4885P2RX2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.